Health and wellness platform Hims & Hers Health Inc (NYSE: HIMS) announced on Wednesday that it has acquired at-home lab testing facility Sigmund NJ LLC, marketed as Trybe Labs, to enhance its personalised healthcare offerings.

This acquisition enables the company to support at-home blood draws and expand testing capabilities across key health markers, including hormone levels, cardiac risk, thyroid function and prostate health.

The new service will provide customers with deeper health insights while equipping providers with critical biomarker data for more precise clinical decision-making. Leveraging this data, Hims & Hers plans to enhance AI-driven tools like MedMatch, moving toward an AI-powered healthcare model offering affordable, high-quality, and customised treatments.

With the expansion, Hims & Hers aims to enter high-impact clinical categories such as low testosterone and menopausal support. The company funded the acquisition through cash on hand and expects to roll out at-home testing over the next year, further strengthening its position as a leading digital health platform.